Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
Ozgul Muneyyirci-Delale, David F Archer, Charlotte D Owens, Kurt T Barnhart, Linda D Bradley, Eve Feinberg, Veronica Gillispie, Sandra Hurtado, Jin Hee Kim, Alice Wang, Hui Wang, Elizabeth A Stewart, Ozgul Muneyyirci-Delale, David F Archer, Charlotte D Owens, Kurt T Barnhart, Linda D Bradley, Eve Feinberg, Veronica Gillispie, Sandra Hurtado, Jin Hee Kim, Alice Wang, Hui Wang, Elizabeth A Stewart
Abstract
Objective: To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing heavy menstrual bleeding in women with uterine fibroids.
Design: Pooled analysis of two identical, double-blind, randomized, placebo-controlled, 6-month phase 3 trials (Elaris Uterine Fibroids [UF]-1 and UF-2).
Setting: A total of 153 gynecological clinical care settings in the United States and Canada.
Patients: Premenopausal women (18-51 years) with >80 mL of menstrual blood loss (MBL)/cycle and uterine fibroids with and without coexisting adenomyosis diagnosed by ultrasound and/or magnetic resonance imaging at baseline.
Interventions: Participants were randomized 1:1:2 to placebo, elagolix 300 mg twice daily alone, or elagolix 300 mg twice daily with estradiol 1 mg/norethindrone acetate 0.5 mg once daily.
Main outcome measures: The primary endpoint was the proportion of women who had <80 mL of MBL during the final month and ≥50% reduction in MBL from baseline to the final month. Adverse events were monitored.
Results: Of 786 women treated across the two trials, 16% (126 women) had coexisting adenomyosis. Among this subset, a significantly greater proportion of women who received elagolix with add-back therapy (77.1% [95% confidence interval, 66.2, 88.0]) met both primary endpoint criteria compared with women who received placebo (12.2% [95% confidence interval, 1.0, 23.4]). Adverse events most frequently reported in the elagolix with add-back adenomyosis subset were hot flushes (18.3%), nausea (11.7%), and night sweats (8.3%).
Conclusions: Elagolix with add-back therapy significantly reduced heavy menstrual bleeding in women with uterine fibroids and coexisting adenomyosis, suggesting that elagolix efficacy was not adversely affected by the presence of adenomyosis (Elaris UF-1 and UF-2 Clinical-Trials.gov numbers, NCT02654054 and NCT02691494).
Keywords: Adenomyosis; elagolix; uterine fibroids.
© 2021 The Author(s).
Figures
References
- Taran F.A., Weaver A.L., Coddington C.C., Stewart E.A. Characteristics indicating adenomyosis coexisting with leiomyomas: a case-control study. Hum Reprod. 2010;25:1177–1182.
- Brucker S.Y., Huebner M., Wallwiener M., Stewart E.A., Ebersoll S., Schoenfisch B. Clinical characteristics indicating adenomyosis coexisting with leiomyomas: a retrospective, questionnaire-based study. Fertil Steril. 2014;101:237–241.e1.
- Stewart E.A. Uterine fibroids. Lancet. 2001;357:293–298.
- Bergholt T., Eriksen L., Berendt N., Jacobsen M., Hertz J.B. Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod. 2001;16:2418–2421.
- Weiss G., Maseelall P., Schott L.L., Brockwell S.E., Schocken M., Johnston J.M. Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women's Health across the Nation (SWAN) Fertil Steril. 2009;91:201–206.
- Nelsen L.M., Lenderking W.R., Pokrzywinski R., Balantac Z., Black L., Pokras S. Experience of symptoms and disease impact in patients with adenomyosis. Patient. 2018;11:319–328.
- Fuldeore M., Yang H., Soliman A.M., Winkel C. Healthcare utilization and costs among women diagnosed with uterine fibroids: a longitudinal evaluation for 5 years pre- and post-diagnosis. Curr Med Res Opin. 2015;31:1719–1731.
- Soliman A.M., Margolis M.K., Castelli-Haley J., Fuldeore M.J., Owens C.D., Coyne K.S. Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. Curr Med Res Opin. 2017;33:1971–1978.
- Zimmermann A., Bernuit D., Gerlinger C., Schaefers M., Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6.
- Pontis A., D'Alterio M.N., Pirarba S., de Angelis C., Tinelli R., Angioni S. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016;32:696–700.
- American College of Obstetricians and Gynecologists ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112:387–400.
- Dessouky R., Gamil S.A., Nada M.G., Mousa R., Libda Y. Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy. Insights Imaging. 2019;10:48.
- Diamond M.P., Carr B., Dmowski W.P., Koltun W., O’Brien C., Jiang P. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21:363–371.
- Ng J., Chwalisz K., Carter D.C., Klein C.E. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102:1683–1691.
- Schlaff W.D., Ackerman R.T., Al-Hendy A., Archer D.F., Barnhart K.T., Bradley L.D. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382:328–340.
- Stewart E.A. In: UpToDate: Wolters Kluwer. Robert L., Barbieri D.L., Chakrabarti A., editors. 2020. Uterine adenomyosis.
- Taran F.A., Weaver A.L., Coddington C.C., Stewart E.A. Understanding adenomyosis: a case control study. Fertil Steril. 2010;94:1223–1228.
- Vercellini P., Parazzini F., Oldani S., Panazza S., Bramante T., Crosignani P.G. Adenomyosis at hysterectomy: a study on frequency distribution and patient characteristics. Hum Reprod. 1995;10:1160–1162.
- Parazzini F., Vercellini P., Panazza S., Chatenoud L., Oldani S., Crosignani P.G. Risk factors for adenomyosis. Hum Reprod. 1997;12:1275–1279.
- Vavilis D., Agorastos T., Tzafetas J., Loufopoulos A., Vakiani M., Constantinidis T. Adenomyosis at hysterectomy: prevalence and relationship to operative findings and reproductive and menstrual factors. Clin Exp Obstet Gynecol. 1997;24:36–38.
- Al-Hendy A., Bradley L., Owens C.D., Wang H., Barnhart K.T., Feinberg E. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2020;224:72.e1–72.e50.
- Propst A.M., Quade B.J., Gargiulo A.R., Nowak R.A., Stewart E.A. Adenomyosis demonstrates increased expression of the basic fibroblast growth factor receptor/ligand system compared with autologous endometrium. Menopause. 2001;8:368–371.
- Propst A.M., Quade B.J., Nowak R.A., Stewart E.A. Granulocyte macrophage colony-stimulating factor in adenomyosis and autologous endometrium. J Soc Gynecol Investig. 2002;9:93–97.
Source: PubMed